secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001564590-21-053288
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q3 revenue $810M (+12%), EPS $2.03; raises FY2021 guidance to higher end
------------------------------------------------------------------------------

- Q3 revenue $810M (+12% reported, +10% organic); EPS $2.03 (+20% reported, +12% comparable).
- CAG Diagnostics recurring revenue +13% reported, +11% organic; record Q3 premium instrument placements.
- Updates FY2021 guidance: revenue $3,185-3,200M (17.5-18% growth), EPS $8.30-8.38 (24-25% growth).
- Operating margin 27.9% (+410bps reported, +20bps comparable); benefited from lapping prior year litigation accrual.
- Water revenue +15% reported, +13% organic; LPD revenue declined 21% due to China ASF testing comparison.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000156459021053288/0001564590-21-053288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000156459021053288/idxx-8k_20211102.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-053288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer